New Antibiotic Could Be a Breakthrough in Treatment for Killer TB, Trial Suggests

A new treatment for tuberculosis could boost cure rates and shorten the time needed to treat the disease by months, trial results suggest. The Guardian: Globally, an estimated 10.7 million people fell ill with TB last year and 1.23 million died from it. In its annual report on tuberculosis, launched last week, the World Health Organization said it remained a 'major global public-health problem' and the leading infectious cause of death. Sorfequiline, a new antibiotic, showed stronger action against the deadly bacteria than existing treatments, with a comparable safety profile, researchers from the TB Alliance told the Union Conference on Lung Health in Copenhagen on Wednesday.

The trial involved 309 people across 22 sites in South Africa, the Philippines, Georgia, Tanzania and Uganda, with different dose regimens. All participants had 'drug-sensitive' tuberculosis, meaning a standard cocktail of drugs can safely treat them but researchers believe TB infections that are resistant to standard treatment could also be helped. The trial suggested a sorfequiline-based regimen could be used for anyone testing positive, said Dr Maria Beumont, vice-president of TB Alliance.

Read more of this story at Slashdot.